Pre-submission facility correspondence for generic dosage form with an expedited-approval in 8 months
Keywords:
ANDA, eCTD, PAS, PFC, RLD (Reference listed drug)Abstract
PFC (Pre-Submission Facility Correspondence) is the initial submission for an ANDA (Abbreviated New Drug Application), comprising information for the application similar to the original ANDA, and only valid in the United States Agency For a pre-determined inspection of the finished drug product's facility information. The Applicant can be introducing their Drug Product into the Market before the ANDA's Goal date of 8 months, according to the Pre-Submission Facility Correspondence. The submission type Original ANDA, PAS (Prior approval supplement), and PAS Amendment is based on prior review goal submission. The FDA (Food and Drug Administration) approves PFC submission for a range of reasons, including drug product shortfalls, COVID-19 emergency dosage medication, Patent paragraph-IV (patent is invalid or will not be infringed), and market-availability of one RLD (Reference listed drug) and one generic. The complete submission process gone through the eCTD submission format from the ESG (Electronic Submission Gateway).
Downloads
References
Teva api. 2022. FDA Priority ANDA Review and Teva api support | Teva api.
https://www.teva-api.com/knowledge-center/fda-priority-anda-review-and-teva-api-support
U.S. Food and Drug Administration. 2022. Submission Review. https://www.fda.gov/industry/generic-drug-user-fee-amendments/submission-review
Fda.gov. 2022. Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry.
Govinfo.gov. 2022. Part 314 - Applications for FDA Approval to Market a New Drug. https://www.govinfo.gov/content/pkg/CFR-2018-title21-vol5/pdf/CFR-2018-title21-vol5-sec314-94.pdf
Fda.gov. 2022. Generic Drug Labeling Revisions Covered Under Section 505(j)(10) of the Federal Food, Drug, and Cosmetic. Act https://www.fda.gov/media/85152/download#:~:text=Section%20505(j)(10)%20permits%20the%20Food%20and%20Drug,reference%20listed%20drug%20(RLD)
Fda.gov. 2022. ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence). https://www.fda.gov/media/105794/download
Fda.gov. 2022. Competitive Generic Therapies Guidance for Industry. https://www.fda.gov/media/136063/download
E. Saravana Kumar, K.Vengatesan, R. P. Singh, C.Rajan,” Biclustering of Gene Expression data using Biclustering Iterative Signature Algorithm and Biclustering Coherent Column, International Journal of Biomedical Engineering and Technology, vol.26, isuue3-4,pp. 341-352, 2018.
U.S. Food and Drug Administration. 2022. Paragraph IV Drug Product Applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-drug-product-applications-generic-drug-patent-challenge-notifications
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
